The neurokinin receptor antagonists A3914 and A5425 are potent on both the NK1 and NK2 receptors. The first molecule in the series is ready to be moved into man and is currently being evaluated for use in dermatology (atopic dermatitis and psoriasis) and for prevention of adhesions/excessive scarring after surgery.
Atopic dermatitis and psoriasis are chronic immune-mediated diseases often accompanied with severe pruritus. There is a great need for more efficacious and safer treatment alternatives. Both preclinical and clinical data support NK as a promising target for treatment of skin disorders.